Genexine’s Long-acting Anemia Treatment GX-E4 Phase 3 Clinical Trial Interim Result Is Presented at WCN2023, Confirmed Non-inferiority Compared to Mircera

A clinical-staged proprietary platform technology biotech company Genexine and its Asian regional partner, KG Bio unveiled the interim results of phase 3 clinical trial of GX-E4, a candidate for CKD induced anemia.